U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07635511) titled 'Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies' on June 01.
Brief Summary: Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of bleeding, but is also strongly associated with graft failure and reduced survival after transplantation. HLA class I antibody-mediated alloimmunization is recognized as the most important immunological cause of PTR. HLA antibodies are directly secreted by plasma cells, which are derived from B cells. Therefore, targetin...